Macular corneal dystrophy
MONDO:0009020Macular corneal dystrophy (MCD) is a rare, severe form of stromal corneal dystrophy characterized by bilateral ill-defined cloudy regions within a hazy stroma, and eventually severe visual impairment.
Also known as: Fehr corneal dystrophy, MCD, corneal dystrophy Groenouw type II, macular corneal dystrophy, Groenouw type 2 corneal dystrophy, Groenouw type II corneal dystrophy, Mcdc1, Mcdc1, formerly
43 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsBroader categories
-
Experimental drug combo tested for rare, deadly castleman disease
Disease control OngoingThis study looks at a rare disease called KSHV-associated multicentric Castleman's disease (MCD), caused by a virus. Researchers are testing several drug combinations, including chemotherapy and antivirals, to see if they can control the disease. The study also tracks how the dis…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Can a donor lens implant restore clarity to clouded corneas?
Disease control ENROLLING_BY_INVITATIONThis trial investigates whether implanting a fresh corneal lenticule — a thin layer of donor cornea taken from myopic patients — can improve transparency and vision in people with macular corneal dystrophy, a condition that clouds the cornea. Using a femtosecond laser, surgeons r…
Phase: NA • Sponsor: Eye Hospital Pristina Kosovo • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Rapamycin drug tested for rare castleman disease
Disease control OngoingThis phase 2 study tests the drug sirolimus (rapamycin) in 7 people with idiopathic multicentric Castleman disease who have not improved with standard therapy. The goal is to see if sirolimus can improve symptoms like fatigue, fever, and night sweats, and shrink enlarged lymph no…
Phase: PHASE2 • Sponsor: University of Pennsylvania • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC